GSK terminates Traficet-EN programme
ChemoCentryx reported that its Crohn's disease drug vercirnon (GSK1605786) failed the first of four Phase III trials supported by GSK and now GSK has terminated the programme. No efficacy was observed with either dose of vercirnon over 12 weeks in SHIELD-1. In addition, dose-dependent increases in rates of adverse events (AEs), gastrointestinal AEs, and cardiac AEs, including two cardiac serious AEs in the 500mg twice daily group, were observed. Those findings have reduced the benefit to risk profile of vercirnon and do not support the continued treatment of the programme.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.